Adhering to current clinical guidance supports evidence-based assessment, informs decision-making, and helps reduce complications in women experiencing menopause. Ongoing review of recommendations and guidance enables clinicians to improve evaluation and management, which supports better patient outcomes.
Today's rundown features clinical guidance that’s been published within the past five years from medical societies including the American College of Obstetricians and Gynecologists (ACOG), the National Institute of Health and Care Excellence (NICE) the North American Menopause Society (NAMS), among others. The guidance is divided into three key categories: menopause assessment and hormone therapy guidance, symptom-specific and nonhormonal management guidance, and special populations and comorbidities guidance.
Menopause Assessment and Hormone Therapy Guidance
- Menopause: Identification and Management
- National Institute for Health and Care Excellence (NICE)
- April 2026
- Women’s Midlife Health and Menopause
- International Menopause Society (IMS)
- December 2025
- Evaluation and Management of Menopause and the Perimenopause
- European Society of Endocrinology (ESE)
- October 2025
- Hormone Therapy Position Statement 2022
- North American Menopause Society (NAMS)
- June 2022
- Compounded Bioidentical Menopausal Hormone Therapy
- American College of Obstetricians and Gynecologists (ACOG)
- November 2023
Symptom-Specific and Nonhormonal Management Guidance
- Genitourinary Syndrome of Menopause (GSM)
- British Menopause Society (BMS)
- March 2026
- Genitourinary Syndrome of Menopause
- American Urogynecologic Society (AUGS), American Urological Association (AUA), Society of Urodynamics Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
- April 2025
- Nonhormonal Management of Menopause-Associated Vasomotor Symptoms
- North American Menopause Society (NAMS)
- June 2023
- Vitamin D and Menopausal Health
- European Menopause and Andropause Society (EMAS)
- December 2022
Special Populations and Comorbidities Guidance
- Hormone Therapy (HT) in Women with Premature Ovarian Insufficiency or Early Menopause
- International Menopause Society (IMS), International Federation of Gynecology and Obstetrics (FIGO)
- August 2025
- Thyroid Disease and Menopause
- European Menopause and Andropause Society (EMAS)
- April 2024
- Premature Ovarian Insufficiency
- European Society of Human Reproduction and Embryology (ESHRE)
- December 2024
Check out our other obstetrics and gynecology content and sign up for alerts to stay informed on the latest published guidelines and insights.